News for ACOR Stock

Acorda Therapeutics Announces Delisting from Nasdaq Acorda Therapeutics Announces Nasdaq Delisting Notification Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024 Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024 Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025 Acorda Therapeutics Reports Third Quarter 2023 Financial Results Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023 Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA® Acorda Therapeutics Reports Second Quarter 2023 Financial Results Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™” Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023 Tom Burns Elected to the Acorda Therapeutics Board of Directors Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A Acorda Therapeutics Reports First Quarter 2023 Financial Results Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023 Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting Acorda Launches INBRIJA® TV Commercial for Parkinson’s Awareness Month Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results ESTEVE Launches INBRIJA® in Spain Acorda Fourth Quarter/Year End 2022 Update: Webcast/Conference Call Scheduled for March 9, 2023 Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement Acorda Therapeutics to Present at Sequire Biotechnology Conference Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA® Acorda Therapeutics Announces Revised Long-Term Financial Guidance Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a Hearing Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders Acorda Therapeutics Reports Third Quarter 2022 Financial Results Acorda Therapeutics Provides Long-Term Business Plan and Financial Guidance Acorda Third Quarter 2022 Update: Webcast/Conference Call Scheduled for November 1, 2022 Acorda Shareholders Invited to Virtual Q&A with CEO Ron Cohen, M.D. Acorda Therapeutics Will Not Use Shares for December 2022 $6.2 Million Interest Payment on Secured Debt Acorda Therapeutics Announces $16.5M Award and Royalty/Supply Relief in AMPYRA® Arbitration Case Acorda Therapeutics Withdraws Proposal to Increase Authorized Shares from Special Meeting of Stockholders Acorda Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals Acorda Therapeutics Announces Resignation of Chief Operating Officer Acorda Therapeutics Reports Second Quarter 2022 Financial Results Acorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled for August 4, 2022 Esteve Launches INBRIJA® in Germany Acorda Therapeutics Reports First Quarter 2022 Financial Results Acorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA® in Latin America Acorda First Quarter 2022 Update: Webcast/Conference Call Scheduled for May 11, 2022 Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results Acorda Fourth Quarter/Year End 2021 Update: Webcast/Conference Call Scheduled for March 9, 2022 Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference John Varian Joins Acorda Therapeutics Board of Directors Acorda Therapeutics Reports Third Quarter 2021 Financial Results, Additions to Leadership Team Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Germany Acorda Third Quarter 2021 Update: Webcast Scheduled for November 9, 2021 Acorda Therapeutics Announces Corporate Restructuring, Management Changes Acorda Therapeutics Reports Second Quarter 2021 Financial Results Acorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021 Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Spain Acorda Therapeutics Announces Repayment of Convertible Senior Notes Acorda Therapeutics Reports First Quarter 2021 Financial Results Acorda Therapeutics First Quarter 2021 Update: Webcast/Conference Call Scheduled for May 6, 2021 Celebrity Chef Zarela Martinez Partners with Acorda Therapeutics on the launch of “A Taste for Life with Zarela℠” Acorda Therapeutics to Present at H.C. Wainwright Global Life Sciences Virtual Conference Acorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results Acorda Fourth Quarter/Year End 2020 Update: Webcast/Conference Call Scheduled for March 4, 2021 Acorda Therapeutics Announces Departure of Chief, Business Operations Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent Acorda Therapeutics Announces Agreement for Sale of Manufacturing Operations and Long-Term Global Supply Agreement for INBRIJA®, Corporate Restructuring, and Enters into “At The Market” Offering Agreement Acorda Therapeutics to Present at 39th Annual J.P. Morgan Health Care Conference Acorda Therapeutics to Present at H.C. Wainwright BIOCONNECT Virtual Conference Acorda Therapeutics Announces Completion of One-for-Six Reverse Stock Split Acorda Reports Third Quarter 2020 Financial Results Acorda Third Quarter 2020 Update: Webcast/Conference Call Scheduled for November 3, 2020